Granulocytes, platelets, and bone marrow cells

Granulocytes, platelets, and bone marrow cells represent a broad collection of hematopoietic cell types and tissues rather than a single molecular target. Granulocytes, which include neutrophils, eosinophils, and basophils, are key components of the innate immune system responsible for responding to infections and mediating inflammation (StatPearls, 2023: NBK470256). Platelets are specialized cell fragments essential for primary hemostasis, acting to plug vascular injuries and initiate the coagulation cascade (StatPearls, 2023: NBK545270). The bone marrow serves as the central hub for hematopoiesis, housing hematopoietic stem cells that differentiate into these various blood lineages (National Cancer Institute, 2024: Bone Marrow). In clinical pharmacology, these cells are frequently monitored as indicators of drug safety, as many systemic therapies can lead to myelosuppression, a condition where bone marrow activity is decreased (National Cancer Institute, 2024: Myelosuppression). While specific receptors found on these cells, such as the Granulocyte Colony-Stimulating Factor Receptor (G-CSFR), are targeted by drugs like filgrastim, the collective grouping of these cells is considered a physiological compartment or a site of off-target toxicity rather than a specific protein or receptor target.

Other names

Hematopoietic cellsMyeloid lineage cellsBlood and bone marrow

Drugs affecting these cells typically act by stimulating lineage-specific receptors (e.g., G-CSFR, TPO-R) or by non-specifically inhibiting DNA replication in rapidly dividing marrow progenitors.